Myeloid cell leukemia-1 expression in cancers of the oral cavity: a scoping review.
Agents targeting Mcl-1
Cancer
Mcl-1
Oral cavity
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
06 May 2022
06 May 2022
Historique:
received:
02
09
2021
accepted:
20
04
2022
entrez:
7
5
2022
pubmed:
8
5
2022
medline:
8
5
2022
Statut:
epublish
Résumé
B cell lymphoma-2 (Bcl-2) family members play important roles in cell survival as well as cell death. The role of myeloid cell leukemia-1 (Mcl-1), an important member of the Bcl-2 family, is well established in hematopoietic malignancies. However, the association between Mcl-1 and oral cavity, cancers is not clearly defined. A scoping review was conducted until June 30, 2021, using four major databases, PubMed, Scopus, Web of Science, and Embase. Medical subject headings keywords for Mcl-1, along with its other identifiers, and head and neck cancers (only oral cavity tumors) were used to evaluate the expression, function, molecular association, and therapeutic approach of Mcl-1 in oral cavity cancers and precancers. Mcl-1 expression was associated with the progression of oral cavity cancers. The molecular mechanism and pathways of Mcl-1 in oral cavity cancers established via experimental results have been highlighted in this review. Moreover, the various synthetic and naturally derived therapeutic agents targeting Mcl-1 have been documented. Based on our present review, Mcl-1 appears to be an effective anticancer target that can be used in the therapeutic management of oral cancers.
Sections du résumé
BACKGROUND
BACKGROUND
B cell lymphoma-2 (Bcl-2) family members play important roles in cell survival as well as cell death. The role of myeloid cell leukemia-1 (Mcl-1), an important member of the Bcl-2 family, is well established in hematopoietic malignancies. However, the association between Mcl-1 and oral cavity, cancers is not clearly defined.
METHODS
METHODS
A scoping review was conducted until June 30, 2021, using four major databases, PubMed, Scopus, Web of Science, and Embase. Medical subject headings keywords for Mcl-1, along with its other identifiers, and head and neck cancers (only oral cavity tumors) were used to evaluate the expression, function, molecular association, and therapeutic approach of Mcl-1 in oral cavity cancers and precancers.
FINDINGS
RESULTS
Mcl-1 expression was associated with the progression of oral cavity cancers. The molecular mechanism and pathways of Mcl-1 in oral cavity cancers established via experimental results have been highlighted in this review. Moreover, the various synthetic and naturally derived therapeutic agents targeting Mcl-1 have been documented.
NOVELTY/IMPROVEMENT
UNASSIGNED
Based on our present review, Mcl-1 appears to be an effective anticancer target that can be used in the therapeutic management of oral cancers.
Identifiants
pubmed: 35524332
doi: 10.1186/s12935-022-02603-0
pii: 10.1186/s12935-022-02603-0
pmc: PMC9074253
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
182Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2015 Mar 04;10(3):e0118551
pubmed: 25738304
Toxicol In Vitro. 2012 Feb;26(1):42-50
pubmed: 22020377
Nat Commun. 2018 Dec 17;9(1):5341
pubmed: 30559424
Int J Oncol. 2015 Nov;47(5):1954-62
pubmed: 26352011
Oncol Lett. 2012 Sep;4(3):489-494
pubmed: 23741248
Int J Oncol. 2019 May;54(5):1579-1590
pubmed: 30896785
Toxicol In Vitro. 2010 Apr;24(3):713-20
pubmed: 20116423
Am J Cancer Res. 2016 Aug 01;6(8):1708-19
pubmed: 27648360
FEBS J. 2021 Mar;288(6):1822-1838
pubmed: 32710568
Food Chem Toxicol. 2016 Nov;97:336-345
pubmed: 27693243
Exp Ther Med. 2013 Mar;5(3):789-792
pubmed: 23403540
Dis Markers. 2011;30(5):229-33
pubmed: 21734342
Oncotarget. 2017 Jan 17;8(3):3946-3956
pubmed: 27992367
Radiol Oncol. 2014 Jan 22;48(1):1-10
pubmed: 24587773
Biol Chem. 2008 Apr;389(4):383-93
pubmed: 18208354
Free Radic Biol Med. 2017 Mar;104:1-9
pubmed: 28057599
Anticancer Res. 2020 Feb;40(2):1007-1014
pubmed: 32014946
PLoS One. 2016 Jan 19;11(1):e0147157
pubmed: 26784960
Clin Cancer Res. 2015 Nov 1;21(21):4831-44
pubmed: 26124202
Int J Mol Sci. 2020 Oct 26;21(21):
pubmed: 33114727
Oncol Lett. 2016 Feb;11(2):1603-1607
pubmed: 26893789
Expert Opin Ther Targets. 2015 Apr;19(4):455-70
pubmed: 25612780
Cell Death Differ. 2020 Feb;27(2):405-419
pubmed: 31907390
Front Pharmacol. 2019 Jul 26;10:784
pubmed: 31404252
Life Sci. 2021 Jan 1;264:118730
pubmed: 33160994
Int J Oncol. 2014 Aug;45(2):667-74
pubmed: 24858379
Genes Dev. 2005 Jun 1;19(11):1294-305
pubmed: 15901672
Apoptosis. 2016 Nov;21(11):1265-1278
pubmed: 27544755
J Pathol. 2009 Feb;217(3):398-407
pubmed: 19009587
Oxid Med Cell Longev. 2016;2016:4350965
pubmed: 26998193
Arch Oral Biol. 2021 Jun;126:105114
pubmed: 33831733
Head Neck. 2016 Apr;38 Suppl 1:E761-70
pubmed: 25914292
Cancer Discov. 2018 Dec;8(12):1566-1581
pubmed: 30185627
Br J Cancer. 2021 Aug;125(4):547-560
pubmed: 34079080
Redox Biol. 2017 Oct;13:608-622
pubmed: 28806703
Pharmacogn Mag. 2014 Aug;10(Suppl 3):S622-9
pubmed: 25298683
Oncotarget. 2016 Mar 29;7(13):16731-44
pubmed: 26934442
Clin Cancer Res. 2012 Oct 15;18(20):5639-49
pubmed: 22929803
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3516-20
pubmed: 7682708
Biomed Res Int. 2014;2014:408683
pubmed: 24864240
Arch Otolaryngol Head Neck Surg. 1999 Apr;125(4):417-22
pubmed: 10208679
Front Oncol. 2018 Nov 20;8:533
pubmed: 30524962
Surg Oncol Clin N Am. 2015 Jul;24(3):491-508
pubmed: 25979396
Oncol Rep. 2008 Jun;19(6):1499-503
pubmed: 18497956
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Nat Prod. 2009 Oct;72(10):1735-40
pubmed: 19754129
Oral Oncol. 2018 Nov;86:105-112
pubmed: 30409290
In Vivo. 2017 Nov-Dec;31(6):1103-1114
pubmed: 29102932
Mol Med Rep. 2017 Nov;16(5):6780-6786
pubmed: 28901451
Trends Cell Biol. 2013 Jan;23(1):22-9
pubmed: 23026029
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3985-3993
pubmed: 31583913
Oncotarget. 2015 Jun 30;6(18):16623-37
pubmed: 26009874
Eur J Pharmacol. 2010 Jun 25;636(1-3):52-8
pubmed: 20371243
Cancer Discov. 2013 Mar;3(3):324-37
pubmed: 23274910
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8632-6
pubmed: 16361547
BMC Cancer. 2012 May 01;12:159
pubmed: 22548841
J Clin Biochem Nutr. 2019 Mar;64(2):97-105
pubmed: 30936621
PLoS One. 2013 Oct 17;8(10):e78006
pubmed: 24147107
Head Neck. 2015 Sep;37(9):1326-35
pubmed: 25043125
J Agric Food Chem. 2012 Mar 14;60(10):2480-9
pubmed: 22313388
J Invest Dermatol. 2009 Jun;129(6):1351-60
pubmed: 19037233
J Pharmacol Sci. 2009 Jul;110(3):344-53
pubmed: 19571464
Oral Oncol. 2016 May;56:84-92
pubmed: 26733183
Br J Cancer. 2017 Oct 10;117(8):1154-1163
pubmed: 28873083
Mol Pharmacol. 2013 Jan;83(1):33-41
pubmed: 23019217
Int J Oncol. 2015 May;46(5):2154-62
pubmed: 25672320
Free Radic Biol Med. 2014 Sep;74:1-13
pubmed: 24952138
Cell Death Dis. 2018 Jan 16;9(2):19
pubmed: 29339815
Cell Death Dis. 2020 Jun 8;11(6):443
pubmed: 32513939
Oral Dis. 2011 Jul;17(5):469-75
pubmed: 21496182
Sci Rep. 2014 Aug 20;4:6098
pubmed: 25139387
Int J Oncol. 2016 Apr;48(4):1749-57
pubmed: 26847145
J Oral Pathol Med. 2018 Oct;47(9):823-829
pubmed: 29924888
Cancer Cell Int. 2020 Aug 26;20:405
pubmed: 32863764
Phytother Res. 2015 Aug;29(8):1145-51
pubmed: 25903972
Integr Cancer Ther. 2014 May;13(3):NP18-28
pubmed: 22505597
J Hematol Oncol. 2021 Apr 21;14(1):67
pubmed: 33883020
J Cell Biochem. 2018 Dec;119(12):10118-10130
pubmed: 30129052
Cell Death Dis. 2017 Feb 9;8(2):e2599
pubmed: 28182008
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
J Oral Pathol Med. 2015 Nov;44(10):785-91
pubmed: 25475012
Sci Rep. 2017 Jul 17;7(1):5600
pubmed: 28717222
Dent Clin North Am. 2020 Jan;64(1):25-37
pubmed: 31735231
Int J Oncol. 2013 Oct;43(4):1103-10
pubmed: 23877711
Int J Mol Med. 2013 Oct;32(4):860-6
pubmed: 23877235
PLoS One. 2014 Nov 19;9(11):e111927
pubmed: 25409302
Int J Oncol. 2020 Jul;57(1):377-385
pubmed: 32467983
PLoS One. 2019 Jul 5;14(7):e0219398
pubmed: 31276572
J Cell Physiol. 2018 Dec;233(12):9437-9446
pubmed: 29968910
Exp Cell Res. 2012 Aug 1;318(13):1564-76
pubmed: 22513214
Head Neck. 2013 Jul;35(7):992-8
pubmed: 22733715
J Oral Pathol Med. 2013 Mar;42(3):257-62
pubmed: 22974427
Oncotarget. 2015 Oct 13;6(31):30831-49
pubmed: 26356821
Oral Oncol. 2010 Sep;46(9):688-93
pubmed: 20729132
BMC Cancer. 2010 Nov 30;10:655
pubmed: 21118500
Blood Rev. 2020 Nov;44:100672
pubmed: 32204955
Phytomedicine. 2018 Jan 15;39:25-32
pubmed: 29433680
Front Oncol. 2021 Mar 03;10:607429
pubmed: 33747896
J Hematol Oncol. 2020 Dec 11;13(1):173
pubmed: 33308268
Med Oral Patol Oral Cir Bucal. 2008 Sep 01;13(9):E582-8
pubmed: 18758404
Aging (Albany NY). 2020 Jul 16;12(14):14355-14364
pubmed: 32675387
Comput Struct Biotechnol J. 2019 Jan 26;17:151-159
pubmed: 30788081
Oncol Lett. 2021 Mar;21(3):236
pubmed: 33613725
Breast. 2017 Aug;34 Suppl 1:S27-S30
pubmed: 28668293
Oral Oncol. 2014 Feb;50(2):120-7
pubmed: 24216166
Blood Adv. 2019 Dec 23;3(24):4202-4214
pubmed: 31856269
Carcinogenesis. 2019 Mar 12;40(1):173-183
pubmed: 30395230
Exp Ther Med. 2014 Jan;7(1):228-232
pubmed: 24348795
Genes Dev. 2000 Jan 1;14(1):23-7
pubmed: 10640272
Oncol Rep. 2021 Jun;45(6):
pubmed: 33907849
Radiat Oncol. 2012 Aug 08;7:135
pubmed: 22873792
Autophagy. 2008 Jul;4(5):600-6
pubmed: 18497563
Am J Surg Pathol. 2014 Feb;38(2):235-8
pubmed: 24418857